Business Context and Reporting Period
This Form 6-K filing by IM Cannabis Corp. covers the month of April 2026. The Company, a foreign private issuer based in Israel, announced the execution of a Note Purchase Agreement with an institutional investor on April 6, 2026, with an expected closing date of April 7, 2026.
Key Financial Metrics and Transaction Details
- Capital Raised: The Company issued a convertible note with a principal amount of US$250,000.
- Net Proceeds: The Company intends to use net proceeds of US$225,000 for general corporate purposes.
- Interest Rate: The Note bears an interest rate of 8.0% per annum, increasing to 14.0% upon an Event of Default.
- Repayment Terms: The Note is not repayable in cash; obligations are satisfied solely through the issuance of Common Shares upon conversion.
- Warrant Issuance: A warrant was issued to purchase up to 272,861 Common Shares at an exercise price of CAD$0.47 per share.
- Conversion Price: Set at the lower of a Fixed Price of $0.339 or 90% of the lowest 20-day volume-weighted average price, subject to a Floor Price of $0.07.
Material Changes and Unusual Items
The filing details a specific financing event rather than a periodic financial report. The material change is the addition of debt and potential equity dilution through the convertible note and warrant structure. The filing does not provide comparative financial data (revenue, profit, cash flow, or margins) for the period, as it is a transaction-specific report.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use the proceeds for general corporate purposes. Management has agreed to file a resale registration statement on Form F-3 within 30 trading days of closing.
Risks and Contingencies: The filing includes extensive forward-looking statement disclaimers and highlights significant risks, including:
- Regulatory compliance in highly regulated jurisdictions.
- Impact of geopolitical conflicts, specifically the Israel-Hamas and Israel-Iran wars, on operations and the medical cannabis industry in Israel.
- Reliance on third-party supply agreements and key personnel.
- Ability to maintain Nasdaq Capital Market listing requirements.
- Uncertainty regarding sustainable profitability and the legalization of medicinal cannabis in Germany.
Investor Verification Checklist
- Verify the actual closing of the Offering on April 7, 2026, and the receipt of the US$225,000 net proceeds.
- Monitor the filing and effectiveness of the Form F-3 Registration Statement for resale of shares.
- Assess the impact of the 4.99% beneficial ownership cap on future conversion mechanics.
- Review the Company's ability to maintain good standing and licenses amidst ongoing geopolitical risks in the Middle East.
- Confirm the Company's continued compliance with Nasdaq listing requirements given the capital structure changes.